Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,992 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation.
Kobayashi S, Kobayashi A, Osawa Y, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Kawamura T, Horiuchi T, Kato S, Maekawa T, Yamamura T, Watanabe J, Harada Y, Harada H, Sato K, Kimura F. Kobayashi S, et al. Among authors: takano k. Leukemia. 2017 Apr;31(4):1020-1022. doi: 10.1038/leu.2017.44. Epub 2017 Feb 14. Leukemia. 2017. PMID: 28194039 No abstract available.
Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
Maekawa T, Osawa Y, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Kawamura T, Horiuchi T, Saga R, Kato S, Yamamura T, Watanabe J, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Kimura F. Maekawa T, et al. Among authors: takano k. Leukemia. 2017 Dec;31(12):2709-2716. doi: 10.1038/leu.2017.112. Epub 2017 Apr 3. Leukemia. 2017. PMID: 28386106
Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.
Okada Y, Sato K, Kobayashi S, Nagao S, Takano K, Teramoto M, Tachi N, Kawamura T, Horiuchi T, Kato S, Saga R, Maekawa T, Yamamura T, Watanabe J, Kobayashi A, Kimura F. Okada Y, et al. Among authors: takano k. Int J Hematol. 2018 Apr;107(4):495-497. doi: 10.1007/s12185-017-2354-6. Epub 2017 Oct 14. Int J Hematol. 2018. PMID: 29032513
Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
Maekawa T, Osawa Y, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Kawamura T, Horiuchi T, Saga R, Kato S, Yamamura T, Watanabe J, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Kimura F. Maekawa T, et al. Among authors: takano k. Leukemia. 2018 Dec;32(12):2729-2730. doi: 10.1038/s41375-018-0237-3. Leukemia. 2018. PMID: 30232464
Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.
Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F. Maekawa T, et al. Among authors: takano k. Blood. 2019 Sep 5;134(10):814-825. doi: 10.1182/blood.2019000051. Epub 2019 Jul 3. Blood. 2019. PMID: 31270105 Free article.
[Bendamustine and rituximab combination therapy for recurrent indolent B-cell lymphomas: a retrospective single-institution study].
Teramoto M, Sone T, Takada K, Ogata H, Saito K, Izumi T, Takano K, Nagao S, Okada Y, Tachi N, Kawamura T, Kato S, Maekawa T, Kobayashi A, Kobayashi S, Sato K, Kimura F. Teramoto M, et al. Among authors: takano k. Rinsho Ketsueki. 2020;61(6):598-604. doi: 10.11406/rinketsu.61.598. Rinsho Ketsueki. 2020. PMID: 32624531 Japanese.
1,992 results